MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:28Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Statins]]
			[[Category:Lipid-lowering agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #22

2026-05-23T03:29:43Z

parser-claude batch MedTemplate pre-fill, Top 300 #22

New page

{{MedTemplate
| generic = Simvastatin
| brand = Zocor
| structure =
| classes = [[:Category:Statins|Statin]], [[:Category:Lipid-lowering_agents|Lipid-lowering agent]]
| uses = <vote slug="hyperlipidemia-use">Hyperlipidemia</vote>, <vote slug="cv-risk-reduction-use">Cardiovascular risk reduction</vote>
| starting_dose = 10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk)
| preparations = 5, 10, 20, 40, 80 mg tablets; 4 mg/mL oral suspension
| fda_max = 40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction)
| pill_id =
| routes = Oral
| onset = LDL lowering at 2 weeks, max by 4 weeks
| duration = 24 hours (evening dosing aligns with overnight HMG-CoA reductase peak)
| halflife = ~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover<ref name="zocor-label">FDA Prescribing Information, Zocor (simvastatin), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019766s108lbl.pdf</ref>
| bioavailability = <5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)<ref name="zocor-label" />
| pregnancy = Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="simvastatin-mech-claim">Simvastatin is an inactive lactone prodrug hydrolyzed to its active β-hydroxy acid, a competitive HMG-CoA reductase inhibitor.</vote> CYP3A4 substrate; clinically extensive drug interactions with macrolides, azoles, calcium channel blockers, and grapefruit. SLCO1B1 polymorphism (rs4149056) markedly raises plasma exposure and myopathy risk; CPIC genotype-guided dosing has the highest level of evidence for simvastatin specifically<ref name="cpic-statin-slco1b1">CPIC Guideline for SLCO1B1, ABCG2, and CYP2C9 and Statin-Associated Musculoskeletal Symptoms, 2022. https://cpicpgx.org/guidelines/cpic-guideline-for-simvastatin-and-slco1b1/</ref>.
}}

== References ==
<references />

Simvastatin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #22